ARUP's Laboratory Test Directory

KRAS Mutation Detection with Reflex to BRAF Codon 600 Mutation Detection : 2001932
[ image for: Additional Technical Information]
Additional Technical Information
  


Mnemonic: KRAS RFLX

Ordering Recommendation: Determine eligibility for anti-EGFR (cetuximab and panitumumab) therapy in patients with metastatic colorectal cancer.
Methodology: Polymerase Chain Reaction/Pyrosequencing
Performed: Sun-Sat
Reported: 10-14 days
Specimen Required: Collect: Tumor tissue.

Specimen Preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect paraffin block from excessive heat. Transport tissue block or 5 unstained 5 micron slides. (Min: 3 slides). Transport block and/or slide(s) in a tissue transport kit (ARUP supply # 47808) available online through eSupply using ARUP Connect™or contact ARUP Client Services at (800) 522-2787.

Storage/Transport Temperature: Room temperature or refrigerated. Ship in cooled container during summer months.

Remarks: Include surgical pathology report. Tissue block will be returned after testing.

Unacceptable Conditions: Frozen specimens. Specimens fixed/processed in alternative fixatives (alcohol, Prefer ®) or heavy metal fixatives (B-4 or B-5). Less than 25 percent tumor in tissue. Decalcified specimens.

Stability (collection to initiation of testing): Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Interpretive Data: Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Note: This assay detects mutations in codons 12, 13, and 61. If KRAS is not detected, BRAF codon 600 Mutation Detection will be performed. Additional charges apply.
CPT Code(s): 88381, 81275, 81403, G0452; if reflexed, add 81210
Cross References: Cetuximab (Erbitux) (KRAS Mutation Detection with Reflex to BRAF Codon 600 Mutation Detection) , Panitumumab (Vectibix) (KRAS Mutation Detection with Reflex to BRAF Codon 600 Mutation Detection)